News
Aspira Women’s Health teams up with BioReference to fight ovarian cancer
Ovarian cancer is the second most common gynaecologic cancer in the US

Two US biotech companies have announced a co-marketing and distribution collaboration to address ovarian cancer.
Aspira Women’s Health has collaborated with BioReference, one of the largest full service specialty laboratories in the US, to co-market and distribute Ova1Plus, Aspira’s FDA-cleared blood tests that detect the risk of ovarian malignancy in women diagnosed with a pelvic mass.
Under terms of the agreement, the sales teams of the two companies will collaborate to sell Ova1Plus to gynaecologists and other women’s healthcare providers nationwide.
The collaboration is hoped to lead to more women being appropriately triaged for surgery and improve patient outcomes.
“We are excited to formally launch our collaboration with BioReference,” said Nicole Sandford, CEO of Aspira Women’s Health.
“Providing more physicians and their patients with access to our ovarian cancer risk assessment products is a top priority for Aspira, and this strategic alliance with BioReference is a significant accelerator.
“Our two organisations are well aligned with similar goals of improving care for women. We have complementary relationships and offerings that will most certainly benefit healthcare providers and the women that they serve.
“I believe this is the start of a long-term relationship that will accelerate the adoption of Ova1Plus and provide incremental revenues at attractive margins for each company,” Sandford added.
Greg Richard, head of strategy and business development at Aspira Women’s Health, said sales professionals from each company will work collaboratively to ensure physicians understand the power of our ovarian cancer risk assessment products to expand market access and provider adoption.
Craig Allen, president and BioReference CEO, said: “We are pleased to offer Ova1Plus to physicians across the country as part of our focus on women’s health and look forward to a successful collaboration with Aspira.
“As women’s health test offerings advance, it becomes more and more imperative to offer women access to information about their health.”
Aspira Women’s Health aims to transform women’s gynaecological health with the discovery, development, and commercialisation of testing options for women of all races and ethnicities.
The company says the blood tests could reduce the falsely elevated rate by up to 50 per cent, maintain the high rate of detection for ovarian cancer risk, continue to provide confidence in low-risk results with a high negative predictive value, and increased specificity by up to 20 per cent.
Diagnosis
AI may help accelerate breast cancer diagnosis for high-risk women – study
Fertility
Infertility may be risk factor for early menopause, study suggests
News
Endometriosis documentary profiles stars including Marilyn Monroe and Amy Schumer

A non-profit has launched an endometriosis documentary featuring Amy Schumer and Marilyn Monroe as it pushes for changes in how the condition is treated and understood.
The Endometriosis Collective has launched to change how endometriosis is researched, treated and understood, starting with a documentary featuring stories from people including Amy Schumer and Marilyn Monroe.
The feature-length documentary, “End of the Cycle”, will premiere in New York on Tuesday, and The Endometriosis Collective is making the film free to stream online.
Schumer, a comedian, writer and actor, has previously spoken of how endometriosis left her “on the floor in pain, vomiting from the pain, the pain that nobody can see.”
Schumer is one of several celebrities featured in the documentary. Other contributors include dancer Julianne Hough, Olympic medallist Brittany Brown and actors Janel Parrish and Folake Olowofoyeku.
The Endometriosis Collective timed the documentary premiere to coincide with the 100th anniversary of Marilyn Monroe’s birth.
Monroe, who died in 1962, starred in films such as “Some Like It Hot” and “Gentlemen Prefer Blondes.”
According to a biography published in 1985, Monroe’s endometriosis was so severe that it destroyed her marriages, her wish for children, her career and ultimately her life.
The Endometriosis Collective said the documentary shares newly uncovered information about Monroe’s experience with endometriosis.
The non-profit said the information connects Monroe’s story to the experiences of women across generations, highlighting how far awareness, research and care still have to go.
A representative of the Marilyn Monroe Estate said: “By sharing this part of her story through ‘End of the Cycle,’ we hope to honour her legacy in a way that brings visibility to endometriosis, encourages more open dialogue and helps inspire the research needed to create change.”
As part of the premiere, The Endometriosis Collective is holding a panel discussion.
Schumer, Brown and Olowofoyeku, the documentary’s co-directors Sammy Jaye and Soraya Simi, and medical experts are due to be part of the premiere.
AbbVie’s Orilissa and Sumitomo Pharma’s Myfembree are among the approved drugs for endometriosis pain.
Hough, one of the participants in the documentary, starred in an Orilissa campaign in 2017.
Menopause1 week agoPerimenopause misinformation ‘putting women at risk’
News4 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Events4 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Insight3 weeks agoPCOS renamed after decade-long campaign to end ‘cyst’ misconception
Events4 weeks agoWHIS 2026 unveils agenda and first speakers for the leading women’s health summit
Menopause4 weeks agoCBT shows promise for menopause insomnia and hot flashes
Hormonal health2 weeks agoNHS urged to update website following renaming of PCOS
News6 days agoThree menopause innovators shortlisted for Femtech World Award















1 Comment